Home > Healthcare > Medical Devices > Diagnostic Devices > Primary Care POC Diagnostics Market

Primary Care POC Diagnostics Market Share

Report ID: GMI7895
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Primary Care POC Diagnostics Market Share

The primary care POC diagnostics industry is consolidated, with key players including, Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories, and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market share.

For instance, in October 2021, Bio-Rad Laboratories launched new CFX Opus 96 Dx System and the CFX Opus 384 Dx System, real-time PCR detection systems. This system offers precise quantification to improve assay development, workflow efficiencies and productivity for diagnostic testing and research. This strategy improved diagnostic test outcomes and enabled in augmenting revenue growth.

Primary Care POC Diagnostics Market Companies

Some of the eminent market participants operating in the primary care POC diagnostics industry include:

Abbott Laboratories
ACON Laboratories, Inc.
Becton, Dickinson, and Company
BioMerieux SA
Bio-Rad Laboratories, Inc
Dexcom, Inc.
Dragerwerk Ag & Co.
F. Hoffmann-La Roche
HemoCue AB (Danaher Corporation)
Nova Biomedical
Siemens Healthineers AG
Sysmex Corporation

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global primary care POC diagnostics industry was valued at USD 18.3 billion in 2023 and is estimated to reach USD 33.6 billion by 2032, owing to the increasing incidence of infectious diseases and chronic conditions including cardiovascular diseases.

The glucose monitoring segment garnered USD 4.5 billion revenue size in the year 2023, driven by the increasing adoption of portable, high convenience, and cost-effectiveness as well as rapid primary POC glucose tests.

U.S. primary care POC diagnostics market accounted for USD 6.9 billion revenue size in 2023 and is predicted to witness substantial growth through 2032, attributed to the increasing government initiatives towards chronic and infectious diseases.

Abbott Laboratories., Sysmex Corporation., ACON Laboratories, Inc., Siemens Healthineers AG., Becton, Dickinson, and Company, Nova Biomedical., BioMerieux SA, Bio-Rad Laboratories, Inc, HemoCue AB (Danaher Corporation)., Dexcom, Inc., HemoCue AB (Danaher Corporation) and Dragerwerk Ag & Co.